Drug Repurposing Market 2035: Innovation, Research & Growth Trends

Introduction

The Global Drug Repurposing Market is experiencing continued growth as pharmaceutical companies, research institutions, and healthcare organizations increasingly explore existing medicines for new therapeutic applications. Drug repurposing can help reduce development time and costs because many candidate drugs already have established safety and pharmacological profiles. Rising demand for faster treatment solutions for cancer, Alzheimer's disease, rare genetic disorders, and other unmet medical needs is further supporting market expansion. Advances in artificial intelligence, data analytics, and drug discovery technologies are also improving the identification of promising repurposing opportunities.

Get Free Sample Of This Premium Report

https://www.decisionsadvisors.com/request-sample/DAR4250

Drug Repurposing Market Insights

The Global Drug Repurposing Market was valued at approximately USD 30.44 Billion in 2024 and is projected to reach around USD 51.10 Billion by 2035.

From 2025 to 2035, the market is expected to grow at a CAGR of 4.82%. The expansion is supported by the growing need for economical approaches to drug development, increasing disease prevalence, technological advancements, and rising interest in addressing unmet medical needs.

Based on Therapeutic Area, the Same Therapeutic Area segment accounted for the largest market share in 2024. Repurposing drugs within the same therapeutic area can benefit from existing clinical knowledge and established treatment applications, potentially supporting faster development and market entry.

Based on Drug Molecule, Biologics dominated the market in 2024 and are projected to grow at a substantial CAGR during the forecast period. Their demonstrated effectiveness and specificity in addressing complex diseases contribute to their role in drug repurposing activities.

Other Key Findings

• Asia-Pacific is anticipated to hold the largest share of the global drug repurposing market over the forecast period.
• Europe is expected to record the fastest growth during the forecast period.
• Growing healthcare infrastructure investments and large patient populations are supporting market development in Asia-Pacific.
• China and India are experiencing increasing demand for repurposed medicines, supported by healthcare accessibility initiatives.
• Artificial intelligence and data analytics are increasingly being applied to identify potential drug candidates and new therapeutic uses.
• Strategic collaborations among pharmaceutical companies, biotechnology firms, academic institutions, and healthcare organizations are supporting innovation.
• Intellectual property complexities and limited financial incentives for repurposed medicines remain important challenges for market participants.

Report Summary

The report provides revenue forecasts at global, regional, and country levels and analyzes market trends, growth drivers, opportunities, challenges, competitive strategies, and recent developments.

Segmentation Covered

Regional Coverage

• North America: U.S., Canada, Mexico
• Europe: Germany, UK, France, Italy, Spain, Russia, Rest of Europe
• Asia-Pacific: China, Japan, India, South Korea, Australia, Rest of Asia-Pacific
• South America: Brazil, Argentina, Rest of South America
• Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa

Report Coverage

The Global Drug Repurposing Market report provides comprehensive coverage of:

• Revenue forecasts and market sizing
• Therapeutic area analysis
• Drug molecule analysis
• Regional and country-level analysis
• Market growth drivers
• Industry trends and opportunities
• Market restraints and challenges
• Competitive landscape
• Company strategies
• Product development and innovation
• Partnerships, mergers, and acquisitions
• Regulatory developments
• Strategic analysis of key market participants

Companies

The key companies profiled in the Global Drug Repurposing Market include:

• AbbVie
• Amgen
• Boehringer Ingelheim
• Cyclica
• Eli Lilly and Company
• GlaxoSmithKline
• Melior Discovery
• Novartis
• Pfizer
• Pharnext
• Recursion Pharmaceuticals
• Revolution Medicines
• Sanofi
• Schwarz Pharma
• Others

Recent Market Developments

• In March 2025, ZonMw and FAST launched the Drug Repurposing Venture Challenge, designed to help researchers and entrepreneurs translate drug-repurposing discoveries into viable business plans.
• In July 2025, the European Medicines Agency (EMA) launched a pilot program focused on drug repurposing and developing pathways intended to facilitate the development of existing medicines for new therapeutic uses.
• In June 2024, the Netherlands launched RARE-NL, a national hub focused on rare-disease drug development and drug repurposing.

Want detailed insights, forecasts, and competitive analysis?

Check out the full Global Drug Repurposing Market report:

https://www.decisionsadvisors.com/reports/drug-repurposing-market